Q-omics provides the consensus-scored BRD7P2 profile across patient tissues and cancer cell-line models. BRD7P2 expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, BRD7P2 is differentially expressed in 8, with the highest sampling consensus in COAD. Additionally, BRD7P2 RNA expression shows 18,392 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight LIHC, COAD, and UVM as cancer lineages where BRD7P2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for BRD7P2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes BRD7P2 survival associations across molecular data types. BRD7P2 RNA expression shows survival associations in the most cancer types (16). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible BRD7P2 RNA expression–survival associations across cancer types. High BRD7P2 expression shows unfavorable associations in LIHC, LUSC and MESO, but favorable associations in THYM, UCS and KIRC. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .002). Together, the overview and detailed table identify LIHC as the clearest survival context for BRD7P2 RNA expression.
This table summarizes BRD7P2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for BRD7P2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. BRD7P2 shows higher tumor expression in COAD, HNSC, LIHC, LUSC, READ and KIRP. The COAD box plot shows higher BRD7P2 RNA expression in tumor versus normal tissue (log2 FC = +0.721, t-test p < 0.001).
This table shows molecular features associated with BRD7P2 in patient tissues and cancer cell lines. In patient samples, BRD7P2 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
